| Standard dosage | 150 mg twice daily |
| 75 mg twice daily (if creatinine clearance 15–30) | |
| Contraindications | Absolute: Active bleeding, renal impairment (creatinine clearance < 15) |
| Relative: Elevated bleeding risk, high-risk activities (extreme sports, certain occupations) | |
| Main drug interactions | Carbamazepine, cyclosporine, dronedarone, antifungals, quinidine, verapamil, rifampin |
| Main side effects | Bleeding, dyspepsia/gastritis |
| Special points | Direct thrombin inhibitor. |
| Similar safety and superior efficacy compared with warfarin [30]. | |
| No INR monitoring required. | |
| Limited interaction with medication and food. | |
| Patients need education regarding bleeding prevention. | |
| No effective method to rapidly reverse anticoagulation effect. | |
| Cost/cost-effectiveness | Non-generic (approximate cost $246 per month). Periodic blood draws not required. |